A3BL · Airofit - Better Breathing, Better Life

There are about 1 billion persons with chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease, of which about 4 million die prematurely each year. These respiratory diseases represent a heavy socio-economic burden to the healthcare system. Just in Europe, the healthcare and lost production costs amount to €82 billion/year. Nevertheless, the existing approaches for exercise-based pulmonary rehabilitation of these patients are expensive, inefficient or slow, and often lack a connected system for a continuous monitoring, leading to poor compliance of patients that often quit treatment.Airofit A/S is bringing to market Airofit – a connected device for the respiratory training of lung muscles, conceived to promote the strengthening of breathing musculature of patients suffering with respiratory problems. Airofit offers several disruptive features, including 1) connection to a smartphone app and Expert module (game changer features) for a real-time, remote but tight monitoring of patients’ progress by its doctors, 2) controllable inhaling and exhaling resistances in a 3) portable and user-friendly technology, and a 4) cost-efficient solution with the lowest market price comparatively to similar solutions for the same market segment.To bridge the remaining steps towards full scale commercialization of Airofit, the company must clinically validate Airofit and make it compliant with medical devices regulatory standards, while consolidating our strategic partnering throughout the medical devices value chain to ensure public acceptance and enough muscle for Airofit production ramp-up. The to-market maturation of Airofit within the present innovation project represents a strategic opportunity yielding a very large business opportunity, opening a potential revenue stream summing up to €209M over the 5-years post market introduction, from which our SME stands to capture over €109M as gross profits, while creating 48 new full-time positions.